Table 3. Subgroup analysis of IC/CCRT versus IC/RT by tumor stage and induction chemotherapy regimen.
| Subgroup | Overall survival | Disease-free survival | Distant metastasis-free survival | Locoregional relapse-free survival | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| T, N stage | ||||||||
| T3-4 | 0.91 (0.65-1.26) | 0.556 | 0.92 (0.67-1.26) | 0.583 | 1.00 (0.64-1.58) | 0.996 | 1.03 (0.54-1.99) | 0.921 |
| N2-3 | 1.14 (0.81-1.60) | 0.462 | 1.23 (0.88-1.71) | 0.233 | 1.33 (0.82-2.18) | 0.254 | 1.68 (0.91-3.12) | 0.100 |
| IC regimen | ||||||||
| PF | 0.59 (0.30-1.15) | 0.121 | 0.56 (0.29-1.07) | 0.079 | 0,52 (0.20-1.31) | 0.165 | 0.51 (0.15-1.66) | 0.259 |
| PT | 0.93 (0.67-1.30) | 0.675 | 1.02 (0.74-1.40) | 0.911 | 1.01 (0.63-1.61) | 0.973 | 1.68 (0.90-3.15) | 0.105 |
| IC cycles | ||||||||
| ≤ 2 cycles | 0.85 (0.63-1.15) | 0.284 | 0.91 (0.69-1.21) | 0.528 | 0.91 (0.60-1.37) | 0.649 | 1.45 0.85-2.46() | 0.172 |
| > 2 cycles | 0.93 (0.33-2.65) | 0.893 | 0.83 (0.33-2.65) | 0.893 | 1,44 (0.24-8.60) | 0.692 | 0.46 (0.04-5.09) | 0.528 |
HR, hazard ratio; CI, confidence interval; PF: cisplatin/fluorouracil; PT: cisplatin/paclitaxel; IC, induction chemotherapy.